Blueprint Medicines Corp (BPMC) Position Lowered by Allianz Asset Management AG

Allianz Asset Management AG decreased its stake in Blueprint Medicines Corp (NASDAQ:BPMC) by 11.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 37,533 shares of the company’s stock after selling 4,897 shares during the period. Allianz Asset Management AG’s holdings in Blueprint Medicines Corp were worth $1,053,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Dumont & Blake Investment Advisors LLC acquired a new position in Blueprint Medicines Corp during the third quarter valued at approximately $267,000. Russell Investments Group Ltd. acquired a new position in Blueprint Medicines Corp during the fourth quarter valued at approximately $305,000. UBS Asset Management Americas Inc. increased its position in Blueprint Medicines Corp by 9.1% in the third quarter. UBS Asset Management Americas Inc. now owns 11,015 shares of the company’s stock valued at $327,000 after buying an additional 915 shares during the period. Citadel Advisors LLC acquired a new position in Blueprint Medicines Corp during the third quarter valued at approximately $554,000. Finally, Federated Investors Inc. PA increased its position in Blueprint Medicines Corp by 24.0% in the fourth quarter. Federated Investors Inc. PA now owns 23,880 shares of the company’s stock valued at $670,000 after buying an additional 4,618 shares during the period. 59.51% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Blueprint Medicines Corp (NASDAQ:BPMC)

Blueprint Medicines Corp (NASDAQ:BPMC) opened at 41.41 on Tuesday. The company has a 50 day moving average of $36.01 and a 200 day moving average of $31.51. Blueprint Medicines Corp has a 52 week low of $13.27 and a 52 week high of $42.42. The stock’s market capitalization is $1.37 billion.

Blueprint Medicines Corp (NASDAQ:BPMC) last announced its earnings results on Thursday, March 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.76) by $0.01. Blueprint Medicines Corp had a negative return on equity of 55.22% and a negative net margin of 270.30%. The business had revenue of $7.69 million for the quarter, compared to analyst estimates of $6.31 million. During the same period in the previous year, the company earned ($0.58) earnings per share. The company’s revenue for the quarter was up 65.9% compared to the same quarter last year. Equities analysts expect that Blueprint Medicines Corp will post ($3.49) EPS for the current fiscal year.

Your IP Address:

Several research analysts have commented on the stock. Wedbush reissued an “outperform” rating and set a $43.00 price target on shares of Blueprint Medicines Corp in a research note on Tuesday, December 6th. Goldman Sachs Group Inc raised shares of Blueprint Medicines Corp from a “neutral” rating to a “buy” rating and set a $52.00 price target on the stock in a research note on Monday, March 13th. Zacks Investment Research raised shares of Blueprint Medicines Corp from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research note on Monday, December 12th. Cowen and Company reissued a “buy” rating and set a $33.19 price target (down from $38.33) on shares of Blueprint Medicines Corp in a research note on Monday, December 5th. Finally, JMP Securities reissued a “buy” rating on shares of Blueprint Medicines Corp in a research note on Thursday, December 1st. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $39.40.

In related news, major shareholder Rock Ventures Ii L.P. Third sold 1,000,000 shares of the business’s stock in a transaction dated Tuesday, February 7th. The stock was sold at an average price of $35.28, for a total value of $35,280,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Mark J. Levin sold 30,000 shares of the business’s stock in a transaction dated Thursday, March 16th. The shares were sold at an average price of $40.88, for a total value of $1,226,400.00. Following the completion of the sale, the insider now directly owns 116,444 shares of the company’s stock, valued at $4,760,230.72. The disclosure for this sale can be found here. 3.93% of the stock is currently owned by insiders.

About Blueprint Medicines Corp

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

5 Day Chart for NASDAQ:BPMC

Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corp (NASDAQ:BPMC).

This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2024613/blueprint-medicines-corp-bpmc-position-lowered-by-allianz-asset-management-ag.html

Receive News & Ratings for Blueprint Medicines Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corp and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.